The Europe wide reduction to healthcare spending has continued, as the UK announces the possibility of drug price reductions of up to 20 per cent.
A consultation on the revisions to the scheme which regulates branded medicine on the NHS has begun, following the recommendation of the Department of Health. The scheme is intended to control the prices of drugs outside of the Pharmaceutical Price Regulation Scheme which negotiates drug prices between industry and governments. The consultation has recommended an adjustment of between 10 and 20 per cent on sales of branded drugs to the NHS.
Lord Howe, the health minister, intends to “get the best possible outcome for all NHS patients” and that by spending more on drugs would harm other areas of NHS spending, so the reduction is beneficial overall.